Compare Neurocrine Biosciences Inc (NBIX) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PPG Industries, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while PPG Industries, Inc. trades at $115.63 (market cap $25.79B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.56% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PPG | |
|---|---|---|
Market Cap | $17.40B | $25.79B |
Sector | Health | Basic Materials |
52-Week High | $180.55 | $131.56 |
52-Week Low | $123.10 | $94.34 |
Enterprise Value | $16.49B | $31.90B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
PPG Industries trades at $115.71, down 1.41% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 results with $15.88B revenue and $1.58B net income, and recently raised its dividend to $0.74 per share, reflecting confidence in cash flow. Analyst consensus is bullish with a $132.20 price target, though Q2 2026 earnings due July 28 are key for near-term direction.
The outlook is positive given solid profitability and dividend growth, but risks include economic sensitivity and debt levels. Upside potential exists if Q2 earnings beat expectations, while a miss could pressure the stock. The current valuation at a P/E of 16.58 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
